Skip to main content
SpringerLink
Log in

Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Low skeletal muscle mass (sarcopenia) has been reported to have an influence on survival and toxicities of chemotherapy in several solid tumors. The impact of sarcopenia on the treatment of ovarian cancers has not been determined. The present study aimed to evaluate correlation between sarcopenia and toxicities of chemotherapy in ovarian cancers.

Methods

Medical charts of the ovarian cancer patients that received chemotherapy with paclitaxel and carboplatin at our hospital between 2010 and 2015 were retrospectively reviewed. Muscle areas of bilateral psoas major muscles at the fifth lumbar vertebra were measured using images obtained by computed tomography. The volume of muscle and clinicopathological factors were evaluated for toxicities of chemotherapy. The protocol of the present study was approved by the institutional review board of our institution.

Results

A total of 76 patients with ovarian cancers were identified, and enrolled in the present study. Median psoas index (PI, the psoas muscle major cross-sectional area divided by the height squared) was 583 mm2/m2 (range 326–999). The patients with low PI developed peripheral neuropathy more frequently compared with those with high PI (32 vs. 11%; P = 0.047). PI value was not associated with other toxicities such as neutropenia and thrombocytopenia. PI value was associated with grade 2 or higher peripheral neuropathy in univariate analysis (OR = 3.92; 95% CI 1.21–15.32; P = 0.02) and multivariate analysis (OR = 3.93; 95% CI 1.17–15.87; P = 0.03).

Conclusions

PI value was significantly associated with peripheral neuropathy induced by combination therapy with paclitaxel and carboplatin in ovarian cancer patients. Although further studies are needed to confirm the results, the volume of skeletal muscle mass could be a potential biomarker to predict toxicities in ovarian cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Solheim TS, Fayers PM, Fladvad T, Tan B, Skorpen F, Fearon K, Baracos VE, Klepstad P, Strasser F, Kaasa S, European Palliative Care Research Collaborative (EPCRC) and the European Pharmacogenetic Study (EPOS) (2012) Is there a genetic cause of appetite loss?-an explorative study in 1853 cancer patients. J Cachexia Sarcopenia Muscle 3(3):191–198

    Article  PubMed Central  Google Scholar 

  2. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755–763

    Article  CAS  PubMed  Google Scholar 

  3. Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58–67

    Article  PubMed  Google Scholar 

  4. Sato T, Aoyama T, Hayashi T, Segami K, Kawabe T, Fujikawa H, Yamada T, Yamamoto N, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, Yoshikawa T (2016) Impact of preoperative hand grip strength on morbidity following gastric cancer surgery. Gastric Cancer 19(3):1008–1015

    Article  PubMed  Google Scholar 

  5. Chemama S, Bayar MA, Lanoy E, Ammari S, Stoclin A, Goéré D, Elias D, Raynard B, Antoun S (2016) Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 23(12):3891–3898

    Article  PubMed  Google Scholar 

  6. Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, Lee KW, Kim DW, Kang SB, Kim KI, Kim CH, Kim JH (2015) Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 23(3):687–694

    Article  PubMed  Google Scholar 

  7. Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T (2016) Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle 7(4):458–466

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kumar A, Moynagh MR, Multinu F, Cliby WA, McGree ME, Weaver AL, Young PM, Bakkum-Gamez JN, Langstraat CL, Dowdy SC, Jatoi A, Mariani A (2016) Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol 142(2):311–316

    Article  PubMed  Google Scholar 

  9. Brewer JR, Morrison G, Dolan ME, Fleming GF (2016) Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 140(1):176–183

    Article  CAS  PubMed  Google Scholar 

  10. Bolis G, Scarfone G, Raspagliesi F, Mangili G, Danese S, Scollo P, Lo Russo D, Villa A, Aimone PD, Scambia G (2010) Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer 46(16):2905–2912

    Article  CAS  PubMed  Google Scholar 

  11. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F, Multicentre Italian Trials in Ovarian cancer (MITO-7).; Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens et du sein (GINECO).; Mario Negri Gynecologic Oncology (MaNGO).; European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10).; Gynecologic Cancer InterGroup (GCIG) Investigators (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396–405

    Article  CAS  Google Scholar 

  12. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Japanese Gynecologic Oncology Group (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338

    Article  CAS  Google Scholar 

  13. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682–1691

    Article  CAS  PubMed  Google Scholar 

  14. Meriggioli MN, Roubenoff R (2015) Prospect for pharmacological therapies to treat skeletal muscle dysfunction. Calcif Tissue Int 96(3):234–242

    Article  CAS  PubMed  Google Scholar 

  15. Mithal A, Bonjour JP, Boonen S, Burckhardt P, Degens H, El Hajj Fuleihan G, Josse R, Lips P, Morales Torres J, Rizzoli R, Yoshimura N, Wahl DA, Cooper C, Dawson-Hughes B, IOF CSA Nutrition Working Group (2013) Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int 24(5):1555–1566

    Article  CAS  PubMed  Google Scholar 

  16. Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB (2012) Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 106(10):1583–1586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank MS. Hiromi Kubota for continuous contribution to our clinical study.

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

    Tomoyuki Yoshikawa & Masashi Takano

  2. Department of Host Defense and Biochemical Research, Graduate School of Medicine, Juntendo University, Tokyo, 113-8431, Japan

    Tomoyuki Yoshikawa & Isao Nagaoka

  3. Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

    Morikazu Miyamoto, Tadashi Aoyama, Hiroaki Soyama, Tomoko Goto, Junko Hirata, Ayako Suzuki, Hidenori Sasa & Kenichi Furuya

  4. Department of Pharmacy, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

    Isao Yajima, Yukihiro Shimizu & Yusuke Aizawa

  5. Department of Nursing, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

    Yuki Suguchi & Miki Moriiwa

  6. Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan

    Hitoshi Tsuda

Authors
  1. Tomoyuki Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Morikazu Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isao Yajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yukihiro Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yusuke Aizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuki Suguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Miki Moriiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tadashi Aoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroaki Soyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tomoko Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Junko Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ayako Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hidenori Sasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Isao Nagaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hitoshi Tsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Kenichi Furuya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masashi Takano.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

The study protocol was approved by the institutional review board of National Defense Medical College.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshikawa, T., Takano, M., Miyamoto, M. et al. Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol 80, 555–561 (2017). https://doi.org/10.1007/s00280-017-3395-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-017-3395-5

Keywords

Search

Navigation